Discovery Sciences, Medicine Design, Pfizer Inc., Groton, CT, USA.
Medicine Design, Pfizer Inc., Cambridge, MA, USA.
Nat Commun. 2024 Aug 31;15(1):7574. doi: 10.1038/s41467-024-52045-7.
The CC chemokine receptor 6 (CCR6) is a potential target for chronic inflammatory diseases. Previously, we reported an active CCR6 structure in complex with its cognate chemokine CCL20, revealing the molecular basis of CCR6 activation. Here, we present two inactive CCR6 structures in ternary complexes with different allosteric antagonists, CCR6/SQA1/OXM1 and CCR6/SQA1/OXM2. The oxomorpholine analogues, OXM1 and OXM2 are highly selective CCR6 antagonists which bind to an extracellular pocket and disrupt the receptor activation network. An energetically favoured U-shaped conformation in solution that resembles the bound form is observed for the active analogues. SQA1 is a squaramide derivative with close-in analogues reported as antagonists of chemokine receptors including CCR6. SQA1 binds to an intracellular pocket which overlaps with the G protein site, stabilizing a closed pocket that is a hallmark of inactive GPCRs. Minimal communication between the two allosteric pockets is observed, in contrast to the prevalent allosteric cooperativity model of GPCRs. This work highlights the versatility of GPCR antagonism by small molecules, complementing previous knowledge of CCR6 activation, and sheds light on drug discovery targeting CCR6.
CC 趋化因子受体 6(CCR6)是慢性炎症性疾病的潜在靶点。此前,我们报道了 CCR6 与其同源趋化因子 CCL20 形成的复合物的活性结构,揭示了 CCR6 激活的分子基础。在这里,我们展示了与两种不同变构拮抗剂结合的三元复合物中的两种非活性 CCR6 结构,即 CCR6/SQA1/OXM1 和 CCR6/SQA1/OXM2。氧吗啉类似物 OXM1 和 OXM2 是高度选择性的 CCR6 拮抗剂,它们结合到细胞外口袋并破坏受体激活网络。对于活性类似物,观察到在溶液中能量有利的 U 形构象,类似于结合形式。SQA1 是一种 squaramide 衍生物,其类似物被报道为包括 CCR6 在内的趋化因子受体的拮抗剂。SQA1 结合到细胞内口袋,该口袋与 G 蛋白结合位点重叠,稳定了一个封闭的口袋,这是无活性 GPCR 的标志。观察到两个变构口袋之间的最小通信,与 GPCR 的普遍变构协同作用模型相反。这项工作突出了小分子对 GPCR 拮抗作用的多功能性,补充了以前对 CCR6 激活的认识,并为靶向 CCR6 的药物发现提供了启示。